Tarveda’s Phase II Miniature Drug Conjugates Deliver Better Targeting, Less Toxicity than ADCs

Tarveda Therapeutics is advancing its miniature drug conjugates into Phase IIa trials, using a platform that combines the best aspects of small molecules and antibody drug conjugates while addressing their deficiencies. Specifically, the platform, dubbed Pentarin®, delivers more precise oncology medicine for patients with solid tumor malignancies and, therefore, minimizes toxicity to healthy tissue.